Your browser is no longer supported. Please, upgrade your browser.
Settings
ACRX AcelRx Pharmaceuticals, Inc. daily Stock Chart
ACRX [NASD]
AcelRx Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.05 Insider Own0.20% Shs Outstand44.67M Perf Week15.87%
Market Cap163.05M Forward P/E- EPS next Y-0.86 Insider Trans-90.74% Shs Float44.60M Perf Month52.08%
Income-47.70M PEG- EPS next Q-0.28 Inst Own52.10% Short Float7.67% Perf Quarter40.38%
Sales17.40M P/S9.37 EPS this Y-72.90% Inst Trans0.09% Short Ratio4.87 Perf Half Y40.38%
Book/sh-0.43 P/B- EPS next Y25.20% ROA-46.80% Target Price7.60 Perf Year22.48%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range1.95 - 4.08 Perf YTD40.38%
Dividend- P/FCF- EPS past 5Y3.80% ROI-35.70% 52W High-10.52% Beta2.85
Dividend %- Quick Ratio6.00 Sales past 5Y74.50% Gross Margin26.40% 52W Low87.18% ATR0.24
Employees39 Current Ratio6.10 Sales Q/Q3.30% Oper. Margin- RSI (14)77.61 Volatility8.93% 8.43%
OptionableYes Debt/Eq- EPS Q/Q-41.40% Profit Margin- Rel Volume3.30 Prev Close3.15
ShortableYes LT Debt/Eq- EarningsAug 03 AMC Payout- Avg Volume702.78K Price3.65
Recom2.20 SMA2052.48% SMA5049.68% SMA20029.55% Volume2,318,517 Change15.87%
Jul-14-17Resumed Jefferies Buy $7
Sep-15-16Reiterated ROTH Capital Buy $11.25 → $15
Aug-05-16Downgrade Stifel Buy → Hold
Oct-30-15Upgrade Jefferies Hold → Buy
Oct-05-15Reiterated ROTH Capital Buy $8.50 → $10.50
Sep-02-15Initiated H.C. Wainwright Buy $8.50
Jul-10-15Resumed ROTH Capital Buy $7.50
May-06-15Reiterated Mizuho Neutral $5.50 → $3
May-05-15Reiterated RBC Capital Mkts Outperform $8 → $7
Mar-10-15Reiterated RBC Capital Mkts Outperform $12 → $8
Mar-09-15Downgrade Mizuho Buy → Neutral $14 → $5.59
Feb-26-15Upgrade Mizuho Neutral → Buy $6 → $14
Nov-06-14Downgrade Mizuho Buy → Neutral $15 → $6
Sep-26-14Downgrade ROTH Capital Buy → Neutral
Jul-28-14Reiterated RBC Capital Mkts Outperform $15 → $12
Jul-28-14Reiterated Mizuho Buy $20 → $15
Jul-28-14Downgrade Canaccord Genuity Buy → Hold
Apr-17-14Initiated Canaccord Genuity Buy $16
Jan-07-14Initiated RBC Capital Mkts Outperform $15
Dec-19-13Reiterated Mizuho Buy $18 → $20
Jul-24-17 04:30PM  AcelRx Pharmaceuticals to Hold Second Quarter 2017 Financial Results Conference Call and Webcast on Wednesday, August 2nd PR Newswire +15.87%
Jul-19-17 07:00AM  AcelRx Pharmaceuticals Appoints Raffi Asadorian as Chief Financial Officer PR Newswire
Jul-17-17 08:50AM  Today's Research Reports on Stocks to Watch: AcelRx Pharmaceuticals and Sangamo Therapeutics Accesswire +31.25%
Jul-14-17 10:52AM  Jefferies Sees Strong Upside in AcelRx Pharmaceuticals Shares and Set a $7 Price Target SmarterAnalyst +11.63%
Jul-12-17 02:06PM  ETFs with exposure to AcelRx Pharmaceuticals, Inc. : July 12, 2017 Capital Cube
Jun-30-17 02:39PM  ETFs with exposure to AcelRx Pharmaceuticals, Inc. : June 30, 2017 Capital Cube
Jun-28-17 04:22PM  5 Biotech Stocks With Major Catalysts in July Motley Fool
Jun-13-17 12:13PM  ETFs with exposure to AcelRx Pharmaceuticals, Inc. : June 13, 2017 Capital Cube +7.95%
Jun-01-17 07:00AM  AcelRx Pharmaceuticals' ZALVISO Recognized for Innovative Design with Prestigious Red Dot Award PR Newswire
May-31-17 07:00AM  AcelRx Pharmaceuticals to Present at Jefferies 2017 Global Healthcare Conference PR Newswire
May-22-17 01:18PM  ETFs with exposure to AcelRx Pharmaceuticals, Inc. : May 22, 2017 Capital Cube
May-11-17 04:00PM  ETFs with exposure to AcelRx Pharmaceuticals, Inc. : May 11, 2017 Capital Cube
May-10-17 11:46AM  AcelRx Pharmaceuticals, Inc. :ACRX-US: Earnings Analysis: Q1, 2017 By the Numbers : May 10, 2017 Capital Cube
May-08-17 04:13PM  AcelRx Pharmaceuticals reports 1Q loss Associated Press +5.56%
04:01PM  AcelRx Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Corporate Update PR Newswire
09:00AM  Investor Network: AcelRx Pharmaceuticals, Inc. to Host Earnings Call Accesswire
Apr-26-17 07:00AM  AcelRx Pharmaceuticals to Hold First Quarter 2017 Financial Results Conference Call and Webcast on Monday, May 8th, 2017 PR Newswire
Apr-13-17 07:00AM  AcelRx Pharmaceuticals Reports Publication of Manuscripts Analyzing IV, Transdermal and Sublingual Patient-Controlled Analgesia Systems PR Newswire
Apr-11-17 02:10PM  ETFs with exposure to AcelRx Pharmaceuticals, Inc. : April 11, 2017 Capital Cube
Apr-06-17 07:00AM  AcelRx Pharmaceuticals Presenting Comprehensive DSUVIA Clinical Trial Results at ASRA's Annual Regional Anesthesiology and Acute Pain Medicine Meeting PR Newswire
Apr-04-17 11:37AM  Edited Transcript of ACRX earnings conference call or presentation 2-Mar-17 9:30pm GMT Thomson Reuters StreetEvents
Mar-28-17 07:00AM  European Medicines Agency Begins Evaluation of Marketing Application for Sublingual Sufentanil 30 mcg Tablet (ARX-04) for Moderate-to-Severe Acute Pain PR Newswire
Mar-27-17 03:46PM  ETFs with exposure to AcelRx Pharmaceuticals, Inc. : March 27, 2017 Capital Cube
Mar-20-17 08:46AM  AcelRx Pharmaceuticals, Inc. :ACRX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017 Capital Cube
Mar-17-17 07:00AM  AcelRx Pharmaceuticals to Participate at Three Upcoming Investor Events in March and April PR Newswire
Mar-16-17 03:19PM  AcelRx Pharmaceuticals, Inc. to Present at The MicroCap Conference on April 4th in New York City at the Essex House Accesswire
07:00AM  AcelRx Pharmaceuticals Presents Efficacy and Pharmacokinetics of DSUVIA at Upcoming Congresses PR Newswire
Mar-14-17 03:04PM  AcelRx Pharmaceuticals, Inc. :ACRX-US: Earnings Analysis: 2016 By the Numbers : March 14, 2017 Capital Cube
Mar-10-17 07:13AM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and E
Mar-08-17 01:04PM  ACELRX PHARMACEUTICALS INC Financials
Mar-07-17 06:05AM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Mar-03-17 06:07AM  ACELRX PHARMACEUTICALS INC Files SEC form 10-K, Annual Report +6.25%
Mar-02-17 04:30PM  AcelRx Pharmaceuticals Inc Earnings Call scheduled for 4:30 pm ET today
04:14PM  AcelRx Pharmaceuticals reports 4Q loss Associated Press
04:01PM  AcelRx Pharmaceuticals Reports Fourth Quarter and Year End 2016 Financial Results PR Newswire
07:07AM  Q4 2016 AcelRx Pharmaceuticals Inc Earnings Release - After Market Close
Mar-01-17 07:00AM  AcelRx Pharmaceuticals to Participate at Two Upcoming Investor Events in March PR Newswire
Feb-27-17 07:00AM  AcelRx Pharmaceuticals' New Drug Application for DSUVIA Accepted for Filing with PDUFA Date of October 12, 2017 PR Newswire +6.67%
Feb-23-17 04:01PM  AcelRx Pharmaceuticals to Hold Annual 2016 Financial Results Conference Call and Webcast on Thursday, March 2nd, 2017 PR Newswire
Feb-16-17 04:48PM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers
04:45PM  AcelRx Pharmaceuticals Appoints Vincent J. Angotti Chief Executive Officer PR Newswire
Feb-13-17 07:00AM  AcelRx Pharmaceuticals Presentation at JAB Burn Symposium Highlights Potential of DSUVIA for Use in Burn Victims with Moderate-to-Severe Acute Pain PR Newswire
Feb-09-17 05:31PM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Ex +6.90%
Feb-07-17 07:00AM  AcelRx Pharmaceuticals to Participate at Four Upcoming Investor Events in February PR Newswire
Feb-06-17 08:00AM  AcelRx Pharmaceuticals (ACRX) in Focus: Stock Rises 5.3%
Jan-17-17 05:03PM  [$$] Theranos Creates Another Advisory Board at The Wall Street Journal
Jan-09-17 06:19AM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosur
Jan-08-17 08:02AM  AcelRx Pharmaceuticals Provides Guidance on 2017 Milestones for ARX-04, now known as DSUVIA in the United States, for the Treatment of Moderate-to-Severe Acute Pain PR Newswire
08:00AM  AcelRx Pharmaceuticals Announces DSUVIA as Brand Name for ARX-04 in the United States PR Newswire
Dec-22-16 12:10PM  The Story of AcelRx (ACRX), an Innovator in Developing & Commercializing Therapies for the Treatment of Acute Pain Accesswire
Dec-15-16 01:58AM  Does AcelRx Pharmaceuticals Inc (ACRX) Stack Up Against Its Peers? at Insider Monkey
Dec-13-16 11:06AM  ETFs with exposure to AcelRx Pharmaceuticals, Inc. : December 13, 2016
07:01AM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
07:00AM  AcelRx Pharmaceuticals Submits New Drug Application for ARX-04 for the Treatment of Moderate-To-Severe Acute Pain PR Newswire
Dec-06-16 07:00AM  AcelRx Pharmaceuticals Reports on ARX-04 Market and Landscape Presented at Analyst & Investor Event PR Newswire
Dec-01-16 08:36AM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits -8.06%
Nov-28-16 07:00AM  AcelRx Pharmaceuticals Updates Agenda for Analyst & Investor Event Focusing on Innovative Therapies for Treatment of Acute Pain PR Newswire
Nov-21-16 10:10AM  Edited Transcript of ACRX earnings conference call or presentation 1-Nov-16 8:30pm GMT
Nov-17-16 07:00AM  AcelRx Pharmaceuticals Unveiling Results of ARX-04 SAP303 Study in Post-Operative Setting at the Annual ASRA Pain Medicine Meeting PR Newswire
Nov-09-16 07:00AM  AcelRx Pharmaceuticals to Host Analyst & Investor Event on December 1, 2016 PR Newswire +10.91%
Nov-08-16 07:00AM  AcelRx Pharmaceuticals to Participate at Three Upcoming Investor Events in November PR Newswire
Nov-04-16 12:23PM  ETFs with exposure to AcelRx Pharmaceuticals, Inc. : November 4, 2016
Nov-03-16 10:54AM  AcelRx Pharmaceuticals, Inc. :ACRX-US: Earnings Analysis: Q3, 2016 By the Numbers : November 3, 2016 -5.56%
06:11AM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Nov-02-16 06:07AM  ACELRX PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report
Nov-01-16 06:21PM  AcelRx Pharmaceuticals reports 3Q loss
04:08PM  AcelRx Pharmaceuticals Provides Corporate Update and Reports Third Quarter and Nine Months 2016 Financial Results PR Newswire
07:07AM  Q3 2016 AcelRx Pharmaceuticals Inc Earnings Release - After Market Close
Oct-31-16 07:00AM  AcelRx Pharmaceuticals to Present ARX-04 Analysis for Treatment of Moderate-to-Severe Acute Pain in Obese Patients at The Obesity Society Annual Meeting PR Newswire -5.08%
Oct-25-16 07:00AM  AcelRx Pharmaceuticals to Hold Third Quarter Financial Results Conference Call and Webcast on Tuesday, November 1st, 2016 PR Newswire
Oct-24-16 07:00AM  AcelRx Pharmaceuticals Presenting ARX-04 Clinical Trial Findings at National Conference on Correctional Health Care PR Newswire
Oct-20-16 01:35PM  ETFs with exposure to AcelRx Pharmaceuticals, Inc. : October 20, 2016
Oct-03-16 04:32PM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Finan
Sep-28-16 08:56AM  AcelRx (ACRX) Initiates Phase III IAP312 Study on Zalviso
07:00AM  AcelRx Pharmaceuticals Presenting ARX-04 Clinical Trial Findings and Cost Analysis at European Congress on Emergency Medicine PR Newswire
Sep-27-16 07:04AM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial Statements and Exhib +6.35%
07:00AM  AcelRx Initiates Phase 3 Study of Zalviso® in Patients with Moderate-to-Severe Acute Post-Operative Pain PR Newswire
Sep-22-16 04:01PM  Findings from AcelRx Pharmaceuticals' Phase 3 SAP301 Study of ARX-04 in Abdominoplasty Patients to be Presented at Plastic Surgery Meeting PR Newswire
07:00AM  AcelRx Pharmaceuticals to Present at the Ladenburg Thalmann 2016 Healthcare Conference PR Newswire
Sep-19-16 06:07AM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Sep-16-16 07:20AM  Has AcelRx Pharmaceuticals Hit a Home Run?
Sep-15-16 04:18PM  Here's Why AcelRx Pharmaceuticals (ACRX) Stock Gained Today +9.76%
12:56PM  McDonalds Corporation (MCD), AcelRx Pharmaceuticals Inc. (ACRX) & More: Heres Why These Stocks Are Trending Today at Insider Monkey
09:28AM  Stocks to Watch: Pandora, Aerie, AcelRx, Sarepta, Goodyear, Apogee, GE at The Wall Street Journal
07:52AM  1-AcelRx's opioid painkiller succeeds in key study
06:52AM  AcelRx pain drug found safe in high-risk patients in late-stage study
06:32AM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
06:30AM  AcelRx Reports Positive Results for ARX-04 (sufentanil sublingual tablet, 30 mcg), Including in Elderly Patients and Patients with Organ Impairment, in Third Phase 3 Registration Trial, SAP303 PR Newswire
Sep-14-16 04:01PM  AcelRx Pharmaceuticals to Announce Topline Results in Phase 3 Study of ARX-04 in Patients with Post-Operative Moderate-to-Severe Acute Pain PR Newswire
Aug-31-16 07:00AM  AcelRx Pharmaceuticals to Participate at Two Upcoming Investor Events in September PR Newswire
Aug-29-16 07:00AM  AcelRx Pharmaceuticals Presents Results from Phase 3 Study of ARX04 in the Emergency Department at the International Society for Burn Injuries PR Newswire
Aug-15-16 08:11AM  AcelRx Pharmaceuticals' ARX-04 Final Stage Study Meets Primary Endpoint
07:03AM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial Statements and Exhib
07:00AM  AcelRx Pharmaceuticals' ARX-04 Phase 3 Trial Met its Primary Endpoint, Reduced Pain Intensity in ER Patients with Moderate-to-Severe Acute Pain PR Newswire
Aug-08-16 01:46PM  ETFs with exposure to AcelRx Pharmaceuticals, Inc. : August 8, 2016
Aug-05-16 12:06PM  AcelRx Pharmaceuticals, Inc. :ACRX-US: Earnings Analysis: Q2, 2016 By the Numbers : August 5, 2016
Aug-04-16 08:40AM  AcelRx Pharmaceuticals (ACRX) in Focus: Stock Jumps 5.3% -5.32%
Aug-02-16 07:01AM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Aug-01-16 04:18PM  Edited Transcript of ACRX earnings conference call or presentation 28-Jul-16 8:30pm GMT
07:00AM  AcelRx Pharmaceuticals to Present Initial Results of Phase 3 Study of ARX04 at World Congress of Mountain & Wilderness Medicine PR Newswire
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet, which is in Phase III clinical trial for the treatment of moderate-to-severe acute pain. The company's late-stage investigational product candidate is Zalviso, a pre-programmed and patient-controlled analgesia device that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain. Zalviso is approved in the European Union, Switzerland, Liechtenstein, Iceland, Norway and Australia, or the Territory; and is under development stage in the United States. The company was formerly known as SuRx Pharmaceuticals, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Redwood City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
PERCEPTIVE ADVISORS LLC10% OwnerJun 19Sale2.40875,0002,100,0004,533,728Jun 21 04:45 PM
PERCEPTIVE ADVISORS LLC10% OwnerSep 29Sale3.8897,200377,1175,386,410Sep 30 04:32 PM
PERCEPTIVE ADVISORS LLC10% OwnerSep 28Sale3.96119,300472,3805,483,610Sep 30 04:32 PM
PERCEPTIVE ADVISORS LLC10% OwnerSep 15Sale3.70392,8501,452,8115,602,910Sep 16 04:37 PM